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ABSTRACT
Introduction: To estimate the cost-effective-
ness of insulin degludec (IDeg) versus insulin
glargine U100 (IGlar U100) and new-to-market
basal insulin analogues in patients with diabetes
in order to aid decision-making in a complex
basal insulin market.
Methods: A simple, short-term model was used
to evaluate the costs and effects of treatment
with IDeg versus IGlar U100 over a 12-month
period in patients with type 1 (T1DM) and type
2 diabetes (T2DM) from the perspective of the
UK National Health Service. New-to-market
basal insulin analogues were evaluated in sce-
nario analyses.
Results: IDeg is dominant (more effective and
less costly) versus IGlar U100 in patients with
T1DM and patients with T2DM on a basal-only
therapy regimen (T2DMBOT), and is cost-effec-
tive versus IGlar U100 in patients with T2DM
on a basal-bolus regimen (T2DMB/B). In T1DM,
lower costs are primarily driven by lower insulin
costs, as a result of a lower daily dose of IDeg. In
T2DMBOT, lower overall costs with IDeg are
driven by lower costs of severe hypoglycaemic
events due to the significant reduction in
number of events with IDeg versus IGlar U100.
Improvements in clinical outcomes in all three
patient groups are a result of the reduced inci-
dence of hypoglycaemic events. Sensitivity
analyses demonstrate that the results are robust.
Scenario analyses versus two new-to-market
basal insulin analogues indicate that in patients
with T1DM and T2DMBOT, IDeg is likely to be
highly cost-effective versus IGlar biosimilar
Abasaglar and dominant versus IGlar U300
(Toujeo). In T2DMB/B, IDeg is likely to be
cost-effective versus both comparators, with
incremental cost-effectiveness ratios (ICERs)
below the accepted threshold.
Conclusion: IDeg is a cost-effective alternative
to IGlar U100 for patients with diabetes in the
UK, and it also likely to be cost-effective versus
two new-to-market basal insulin analogues.
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INTRODUCTION
The cost of treating diabetes and its related
complications represents a major economic
burden for healthcare systems. The prevalence
of diabetes is increasing and the global expen-
diture on diabetes is projected to reach $490
billion USD by 2030 [1]. In the UK, diabetes cost
approximately £23.7 billion in 2010/2011, and
it is projected to cost an estimated £39.8 billion
by 2035/2036 [2]. The greatest proportion of
diabetes expenditure is for treatment of micro-
and macrovascular complications, which are
consequences of prolonged hyperglycaemia [2].
A key treatment goal of diabetes therapy is to
keep blood glucose levels within recommended
targets and ultimately limit the development of
diabetes-related complications [3, 4].
Insulin is essential for the treatment of type 1
diabetes (T1DM) [5]. Type 2 diabetes (T2DM) is
a progressive disease and although glycaemic
control can often be achieved with other classes
of glucose-lowering therapies following diag-
nosis, a significant proportion of patients will
eventually need insulin therapy to achieve
optimal blood glucose targets [6]. Insulin is the
most effective method of reducing blood glu-
cose concentrations; however, despite evi-
dence-based consensus guidance and
documented benefits of good glycaemic con-
trol, many patients fail to achieve glycaemic
targets [7]. Key barriers to insulin therapy
include fear and risk of hypoglycaemia, weight
gain, restricted lifestyle, reluctance to inject and
difficulties with complex treatment regimens
[8, 9].
New basal insulin analogues with improved
pharmacodynamic and pharmacokinetic pro-
files, which confer a lower risk of hypogly-
caemia and more flexible dosing schedules,
have been developed with the aim of improving
long-term glycaemic control and the patient’s
experience with basal insulin therapy.
Insulin degludec (IDeg) is a basal insulin
with an ultra-long duration of action (more
than 42 h) and a flat and stable action profile
[10, 11]. It has four times less day-to-day vari-
ability in glucose-lowering effect than insulin
glargine U100 (IGlar U100) [12]. In
meta-analyses of phase 3a clinical trials, IDeg
showed equivalent reductions in HbA1c with a
lower risk of hypoglycaemia versus IGlar U100,
and at a significantly lower daily dose when
compared with IGlar U100 in T1DM (12%
lower) and T2DM basal oral therapy (10%
lower) [13, 14]. The benefits of IDeg have also
been reported in real world clinical practice. A
study of 51 patients in routine practice in the
UK, who were suffering from recurrent hypo-
glycaemia on IGlar U100 or insulin detemir,
found that switching to IDeg resulted in sig-
nificant reductions in hypoglycaemia ([90%)
and improved glycaemic control [15].
With increasing constraints on healthcare
budgets, it is important that new therapies
represent good value for money. Cost-effec-
tiveness models estimate the costs of interven-
tions or services in relation to their expected
health benefits. Cost-effectiveness modelling
helps decision makers determine whether the
health benefits associated with adopting the
novel treatment are worth the cost compared
with existing therapies.
Cost-effectiveness models are developed to
compare the overall costs and health outcomes
of two or more treatments. Results of an eco-
nomic model are typically presented as an
incremental cost-effectiveness ratio (ICER),
which is the difference in cost between one
healthcare intervention and an alternative,
divided by the difference in health effects. A
generally accepted effectiveness measure used
in cost-effectiveness analyses is the quality-ad-
justed life year (QALY). The QALY is an overall
measure of health as a combination of the
duration of life and the health-related quality of
life [16]. The incremental cost-effectiveness per
additional QALY gained (cost/QALY) allows
decision makers to broadly compare across dif-
ferent disease areas to determine where the
provision of healthcare resources will lead to
maximal economic and clinical benefits. A
financial threshold is often set at which
cost-effectiveness is accepted. For the National
Institute for Health and Care Excellence, this is
£20,000–£30,000/QALY [17].
Previous cost-effectiveness analyses, using a
short-term model and data from the phase 3a
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clinical trials, have demonstrated that IDeg is
cost-effective versus IGlar U100 in patients with
T1DM and T2DM on basal oral therapy [18–20].
However, since the publication of those evalu-
ations, new basal insulin analogues have come
to market: IGlar U300 (Toujeo) and IGlar
biosimilar (Abasaglar), thus adding more
therapeutic options for patients and crowding
the basal insulin analogue market. Furthermore,
the list price for IDeg was lowered by 35% in
July 2016.
The objective of this study was to re-evaluate
the cost-effectiveness of IDeg versus IGlar U100
from the perspective of the UK National Health
Service, in light of the recent reduction in price
of IDeg and the addition of new basal insulin
analogues to the market place. The revised
model evaluates a more generalisable patient




This cost-utility analysis compared IDeg with
IGlar U100 in three separate patient groups;
type 1 diabetes mellitus using a basal-bolus
regimen (T1DM); type 2 diabetes mellitus using
a basal oral therapy regimen (T2DMBOT); and
T2DM using a basal-bolus regimen (T2DMB/B).
IGlar U100 is currently the most widely pre-
scribed basal insulin in the UK and was there-
fore selected as the comparator for the base case
analysis, but sensitivity analyses explored the
cost-effectiveness of IDeg versus the most recent
additions to the basal insulin market.
This short-term model (one-year time hori-
zon) has been previously published [18–20].
Here we used the same modelling framework,
with updated data inputs where appropriate.
The analysis was conducted from the perspec-
tive of the UK National Health Service. This
simple and transparent model in Microsoft
Excel 2010 (Microsoft Corporation, Redmond,
WA, USA) calculated the costs associated with
treatment and hypoglycaemic events and cal-
culated QALYs by applying a disutility per
hypoglycaemic event (Fig. 1).
DATA USED IN THE MODEL
Clinical Data
Clinical data used in the analysis were derived
from the IDeg clinical trial programme. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Insulin Dose
Units of insulin used per day for the IDeg and
IGlarU100 treatment groupswere the endof trial
doses captured from the clinical trial data. The
IGlar U100 dose and IDeg/IGlar U100 dose ratio
were derived fromameta-analysis of insulin dose
[14]. The IDeg dose was calculated using the dose
ratio to allow for adjustment of covariate factors
such as trial, treatment, antidiabetic therapy at
screening, age, sex, region, and baseline dose
(Table 1). The doses used may be higher than
would be expected in usual clinical practice, but
using these documented doses seen in the
treat-to-target trials allows for a fair comparison.
Needle Use
One needle per day for the T2DMBOT regimen
and four needles per day for both the T1DM and
T2DMB/B regimens were assumed. This was
based on the Forum for Injection Technique
(FIT) recommendations for needle use in the UK
and guidance from needle manufacturers,
which recommends that pen needles should be
used only once [21]. Sensitivity analysis
explored the results for when IGlar U100 was
used twice daily, which is reported to be com-
mon in both T1DM [22, 23] and T2DM [24], due
to the intermediate half-life of current basal
insulin preparations.
Hypoglycaemia Event Rates
Real-world hypoglycaemic event rates from the
UK Hypoglycaemia Study Group (UKHSG)
observational study [25] were used as the base-
line values for severe and non-severe
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hypoglycaemic events. These rates represent
better estimates of real-life event rates than data
from clinical trials. The rates selected from the
UKHSG for the base case analysis were: T1DM
(UKHSG T1DM [15 years): non-severe 29.0
events/patient/year and severe 3.2 events/pa-
tient/year; T2DMBOT (UKHSG T2DM\2 years):
non-severe 4.08 events/patient/year and severe
0.1 events/patient/year; T2DMB/B (UKHSG
T2DM [5 years): non-severe 10.2
events/patient/year and severe 0.7 events/pa-
tient/year. Additional published hypoglycaemia
rates and rates from the clinical trials (Table S1
in the Electronic supplementary material, ESM)
were investigated in sensitivity analyses.
The rates were taken as the base-case event
rates in the IGlar U100 group (as this is the
existing treatment on the market). Event rates
for the IDeg group were calculated using the
relative event rate ratios derived from the
Fig. 1 Overview of the cost-effectiveness model
Table 1 Basal and bolus insulin use






T1DMB/B, total dose 0.88*
Basal insulin 33.10 0.87* 28.80
Bolus insulin 35.00 0.88* 30.80
T2DMBOT, total dose 0.90*
Basal insulin 51.70 0.90* 46.53
Bolus insulin Not relevant Not relevant Not relevant
T2DMB/B, total dose NS
Basal insulin 66.60 1.08* 71.93
Bolus insulin 72.70 NS 72.70
NS nonsigniﬁcant; in the case of nonsigniﬁcant results, a relative rate of 1 was used in the calculation
* p\0.05
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meta-analysis of hypoglycaemia [13, 14] (see
Table 2), and were adjusted for trial, type of
diabetes, treatment, antidiabetic therapy at
screening, sex and region as fixed factors and
age as a continuous covariate. Event rates were
split into three mutually exclusive groups: sev-
ere events, non-severe events occurring during
the day (diurnal) and non-severe events occur-
ring during the night (nocturnal). Since the cost
associated with a severe event is not dependent
on when it occurs and there is no significant
difference in disutility associated with a noc-
turnal versus a daytime severe event, the severe
events were not split into daytime and noctur-
nal. Only rate ratios with a documented statis-
tically significant difference between the
treatment arms were used. This minimised the
influence of random variation on the results.
UTILITY DATA
QALYs were calculated by applying a disutility
[26] per hypoglycaemic event. The disutility per
hypoglycaemic event was multiplied by the
number of events observed in each treatment
group. This was done for severe and non-severe
events separately. A large-scale time trade-off
(TTO) study [26] was used to obtain the disu-
tility incurred per hypoglycaemic event. The
study documented a disutility of 0.0565 for a
severe event (with no significant difference
between daytime and nocturnal severe events)
and disutilities of 0.0041 and 0.0067 for
non-severe daytime and non-severe nocturnal
events, respectively (a significant difference in
utility was demonstrated for nocturnal versus
daytime non-severe events) [26].
COST DATA
Cost of Insulin and Needles
The cost of insulin was calculated based on
prices published in MIMS October 2016 [27] and
daily doses observed in the clinical trials. The
pack price of IDeg (in FlexTouch pen) is £46.60
Table 2 Calculation of hypoglycaemic event rates
T1DMB/B T2DMBOT T2DMB/B
Non-severe Severe Non-severe Severe Non-severe Severe
Baseline hypoglycaemia
rate (IGlar U100)
29 3.20 4.08 0.10 10.2 0.70
Daytime/nocturnal split Daytime Nocturnal – Daytime Nocturnal – Daytime Nocturnal –
86.64% 13.36% 75.34% 24.66% 86.57% 13.43%
Total events per patient
per year for IGlar U100








25.13 3.22 3.20 0.01 0.63 0.01 7.33 1.03 0.70
NS non-signiﬁcant; in the case of non-signiﬁcant results, a relative rate of 1 was used in the calculation
* p\0.05
 Taken from UKHSG [25]
 Proportion of daytime nocturnal events for IGlar, taken from the clinical trials
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for 1500 units, giving a price per unit of £0.031;
IGlar (Lantus in Solostar pen) is £41.50 per
pack for 1500 units, giving a price per unit of
£0.028. The cost of needles was calculated based
on the unit cost and number of daily injections.
Needle choice was assumed to be the same for
all insulins; BD MicroFine (£9.69 per pack of
100 units; price per unit £0.097) was selected as
it is the most commonly used needle in the UK
according to 2015 Prescription Cost Analysis
(PCA) data.
Cost of Hypoglycaemic Events
The cost per hypoglycaemic event (non-severe
nocturnal, non-severe diurnal and severe) was
derived from the published literature.
The cost of a severe hypoglycaemic event,
£173.03/event for T1DM and £414.09/event for
T2DM, was taken from a study specifically
designed to evaluate the cost of severe hypo-
glycaemia across Germany, Spain and the UK
[28]. Costs were inflated using the Health Care
Service Corporation (HCSC) pay and prices
index (from 2008 to 2015), and indirect costs
were excluded.
The cost of a non-severe hypoglycaemic
event was derived from a real-world study that
investigated the frequency of self-reported
non-severe hypoglycaemic events across 11
European countries, including the UK [the
Hypoglycaemia in Insulin Treated Patients
(HIT) study] [29]. The cost in the UK of a
non-severe nocturnal event was £3.36 for T1DM
and £6.35 for T2DM, and for a non-severe
diurnal event it was £2.71 for T1DM and £3.96
for T2DM (exchange rates used: €/£ = 1.36334,
recalculated using 2016 resource use costs).
Alternative published costs, as well as costs
calculated from the clinical trial data, were
investigated in sensitivity analyses.
SENSITIVITY ANALYSES
One-way and probabilistic sensitivity analyses
were conducted in order to assess the impact of
varying key assumptions and outcomes used in
the base case analysis (Table 3).
SCENARIO ANALYSES
Two new basal insulin analogues have recently
entered the market, IGlar U300 (Toujeo) and
IGlar biosimilar (Abasaglar). Given that they
are new to the market, there are currently no
head-to-head data for them versus IDeg. How-
ever, scenario analyses were conducted to eval-
uate the cost-effectiveness of IDeg versus these
comparators using available data and plausible
assumptions.
IDeg versus Abasaglar
This scenario analysis assumed that Abasaglar
has the same efficacy and safety as IGlar U100
(Lantus). However, Abasaglar is a biosimilar
and is not identical to IGlar U100, and EMA
approval does not involve any assessment or
recommendation regarding interchangeability
[33]. The price of Abasaglar is 15% lower than
that of IGlar U100 (Lantus), so this scenario
reflected a 15% reduction in the price of IGlar
U100, with no change in any other parameters.
IDeg versus IGlar U300 (Toujeo)
IGlar U300 is a concentrated insulin glargine
product (300 units/ml) for once-daily use for
the treatment of T1DM and T2DM in adults.
With the IGlar U300 prefilled pen, the maxi-
mum dose per injection is 80U [34]. IGlar U300
has a flatter and more prolonged (up to 36 h)
profile of insulin concentration and glu-
cose-lowering activity compared with IGlar
U100 at the same dose [34]. IGlar U300 is not
bioequivalent to IGlar U100 and they are not
directly interchangeable. An approximately
10–18% higher dose is required when patients
are switched from IGlar U100 to IGlar U300
[34, 35].
In clinical trials, IGlar U300 was non-inferior
to IGlar U100 in terms of HbA1c reduction in
T1DM, T2DMBOT and T2DMB/B [36–38]. In
T1DM, there was no significant difference in
hypoglycaemia (severe, nocturnal or overall)
between IGlar U300 and IGlar U100 [36]; in
T2DMBOT there was no significant difference in
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severe or nocturnal hypoglycaemia but a sig-
nificantly lower rate of overall hypoglycaemia
with IGlar U300 versus IGlar U100 [37]; and in
T2DMB/B there was no significant difference in
severe or overall hypoglycaemia but a signifi-
cantly lower rate of nocturnal hypoglycaemia
with IGlar U300 versus IGlar U100 [38]. In all
three patient groups, the total daily basal
Table 3 Description of sensitivity analyses conducted
Hypoglycaemia rates/
distribution
The base case rate of hypoglycaemia was taken from the published literature as it is believed
that this provides a more realistic event rate. Additional published event rates, and the
actual reported rates from the clinical trial programme, were investigated in sensitivity
analyses
In addition, a sensitivity analysis was conducted where no hypoglycaemia beneﬁt was
assumed for IDeg. As the modelling of QoL is solely dependent on hypoglycaemia, when
there is no hypoglycaemia beneﬁt, there is no difference in QoL between IDeg and IGlar
and an ICER cannot be calculated
Hypoglycaemia distribution The proportion of hypoglycaemic events that occur at night time was also investigated. The
base case proportion was taken from the clinical trials, with sensitivity analysis varying
±50%
Hypoglycaemia costs Sensitivity analyses use alternative published values for costs of both severe and non-severe
hypoglycaemia, and the cost of hypoglycaemia based on the clinical trial data
Hypoglycaemia disutility Base case disutilities were from Evans [26]. Alternative disutilities published by Currie [30]
were explored
Injection frequency For a number of patients, current basal insulins need to be taken twice daily to ensure
optimal control. The effect of using twice as many needles for the basal injections in the
IGlar group was explored
Price The price of IGlar was varied ±15%
Dosing The ﬁnal dose of both IDeg and IGlar and their relationship to each other were investigated
(with either a dose ratio based on the published literature or an assumption of equal doses)
Flexible dosing utility An estimate of the utility beneﬁt of the option of ﬂexible dosing time with IDeg was applied.
Utility values from two published sources were explored [31, 32]
IGlar U300 There are no studies comparing IGlar U300 with IDeg, so sensitivity analyses were
conducted where the price of IGlar U300 was substituted for the price of IGlar U100 and




PSA used the standard errors and appropriate distributions of the parameters. The
distributions were assumed to be either normal or lognormal, and each individual
parameter was selected independently. The probabilistic sensitivity analyses were run with
1000 iterations. In the primary analysis for each of the groups, the standard error was only
applied to differences that were statistically signiﬁcant; i.e. if statistical signiﬁcance was not
proven, the rate ratio was set to 1 (assumed equivalent) and the S.E. was set to 0 (so as not
to introduce random uncertainty)
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insulin dose was higher with IGlar U300 versus
IGlar U100; by 17.5% in T1DM, 17% in
T2DMBOT and 10% in T2DMB/B [36–38].
In this scenario analysis, the cost of IGlar
U300 (£33.13 per pack of 1350 units; £0.025/
unit [27]), calculated based on the IGlar U100
dose observed in the clinical trials and the
reported dose increase for IGlar U300 [34], was
substituted for the IGlar U100 price in the three
patient groups. All other parameters remained
unchanged. It was assumed, based on the IGlar
U300 versus IGlar U100 clinical data and IDeg
versus IGlar U100 clinical data that the hypo-
glycaemia benefit observed with IDeg versus
IGlar U100 would be maintained in this com-
parison versus IGlar U300. However, for trans-
parency, and acknowledging that in a small
number of analyses IGlar U300 had a hypogly-
caemia benefit over IGlar U100, an additional
analysis was conducted where no hypogly-
caemia benefit was assumed for IDeg; i.e. that
IDeg and IGlar U300 have the same clinical
effect. We believe this is conservative, particu-
larly as subjects in the IGlar U300 trials were
transferred dose for dose to IGlar U300, which
means—based on the higher dose requirement
for IGlar U300—that they were underdosed for
the titration stages of the trials.
RESULTS
In T1DM, total costs in the IDeg group are
estimated at £1330 per patient per year
(Table 4). Approximately 52% of this is the cost
of insulin and other pharmacy costs, and the
remainder is other health care costs associated
with hypoglycaemic events, primarily the sev-
ere events. The total cost per patient per year in
the IDeg group is £41 lower than that in the
IGlar U100 group, primarily due to lower insu-
lin costs. The costs of hypoglycaemic events are
almost unchanged due to the fact that only the
non-severe nocturnal events showed a statisti-
cally significant difference between IDeg and
IGlar U100, while the severe and daytime events
were unchanged. IDeg is associated with sig-
nificantly fewer non-severe nocturnal hypogly-
caemic events, which leads to a QALY gain of
0.0044 versus IGlar U100. Thus, IDeg is the
dominant treatment, as it is more effective and
less costly than IGlar U100 (Table 4).
In T2DMBOT, total costs in the IDeg group are
calculated at £585 per patient per year, of which
more than 96% is pharmacy costs (insulin and
needles) and the remainder is costs of hypo-
glycaemic episodes (Table 4). Total costs per
patient per year are £32 lower than in the IGlar
U100 group, driven by lower costs of severe
hypoglycaemic events due to the significant
reduction in the number of severe hypogly-
caemic events with IDeg versus IGlar U100 in
this patient group. Due to the significantly
fewer nocturnal and severe hypoglycaemic
events in this group, IDeg is associated with a
QALY gain of 0.0074 versus IGlar U100. Thus,
IDeg is again the dominant treatment versus
IGlar U100 (Table 4).
In T2DMB/B, the total cost in the IDeg group
is £1825, which is £135 (8%) higher than in the
IGlar U100 group (Table 4). In this setting, 82%
of the costs are pharmacy costs. IDeg is associ-
ated with significantly fewer non-severe day-
time and nocturnal hypoglycaemic events,
which leads to a QALY gain of 0.0084 versus
IGlar U100. The incremental cost per incre-
mental QALY gained with IDeg versus IGlar
U100 is estimated at £15,983 (Table 4). This
result falls below commonly accepted thresh-
olds for cost-effectiveness. The higher incre-
mental cost for this group is driven mainly by
the slightly higher dose of basal insulin required
in the IDeg arm of the clinical trial. In the
T2DMB/B clinical trial [14], high insulin doses
were observed in both the IDeg and the IGlar
U100 treatment arms. The high doses observed
in the trial are not expected to be representative
of a real-world setting for patients initiating a
basal-bolus regimen, as the trial mainly recrui-
ted patients who were already uncontrolled on
an intensive basal-bolus regimen or uncon-
trolled on a pre-mixed insulin regimen.
SENSITIVITY ANALYSIS
In T1DM, the favourable cost-effectiveness
results are robust and invariant to changes in
most of the parameters (Table S2 in the ESM).
When equal insulin doses are assumed, the
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ICER is £8813/QALY gained, or when the price
of IGlar U100 is reduced by 15%, the ICER is
£2027/QALY gained; both of these are well
below commonly accepted thresholds of
cost-effectiveness. The ICER remains dominant
in all other scenarios tested.
A largely similar pattern is observed for the
T2DMBOT treatment regimen. The favourable
cost-effectiveness results are invariant to chan-
ges in most of the parameters, with the ICER
remaining dominant in the majority of analyses
(Table S2 in the ESM). As with T1DM, when
equal insulin doses are assumed or when the
price of IGlar U100 is reduced by 15%, the ICER
is no longer dominant, but it still falls well
below commonly accepted thresholds of
cost-effectiveness (£3609/QALY and £6313/
QALY, respectively).
In the T2DMB/B group, the results fluctuate
above and below the base case ICER of £15,983/
QALY gained, but most results remain below the
threshold of £20,000–£30,000/QALY gained
(Table S2 in the ESM). Varying the rate of
non-severe hypoglycaemia has an impact on
the ICER in this group due to the significant
reduction of non-severe events with IDeg versus
IGlar U100. When the number of non-severe
events/year is reduced to 8.3 using data from
Dornhorst [39], the ICER increases to £19,862/
QALY gained. Conversely, when the annual
number of non-severe hypoglycaemic events is
increased to 48, using data from the real-world
study by Frier [40], the ICER drops to £2640/
QALY gained. The price of IGlar U100 also has a
noticeable impact on the ICER. When the price
of IGlar U100 is reduced by 15%, the ICER is
increased to £27,932/QALY gained, and when
the price of IGlar U100 is increased by 15%, the
ICER is reduced to £4035/QALY gained.
SCENARIO ANALYSIS
IDeg versus Abasaglar
In both the T1DM and the T2DMBOT groups,
IDeg is highly cost-effective versus Abasaglar,
with ICERs of £2027/QALY gained and £6313/
QALY gained, respectively. In T1DM, IDeg is
associated with a £8.94 higher annual per
patient cost and a QALY gain of 0.0044 versus
Abasaglar, and in T2DMBOT it is associated
with a £45.99 higher annual per patient cost
and a 0.0073 QALY gain. In T2DMB/B, the ICER
(£27,932/QALY gained) is on the border of the
commonly accepted threshold of cost-effec-
tiveness. IDeg is associated with a £236.00
higher annual per patient cost and a QALY gain
of 0.0084 in this group versus Abasaglar. In the
T2DMB/B clinical trial [14], high insulin doses
were observed in both the IDeg and the IGlar
U100 treatment arms, which drive the incre-
mental insulin costs up in this analysis.
IDeg versus IGlar U300 (Toujeo)
In both the T1DM and T2DMBOT groups, the
ICER for IDeg versus IGlar U300 is dominant.
Annual per patient costs are £53.36 lower in
T1DM and £52.12 lower in T2DMBOT with IDeg
versus IGlar U300, primarily due to the
increased basal insulin dose with IGlar U300
(17.5% increase in T1DM [36], and 17% increase
in T2DMBOT [37]). IDeg is associated with QALY
gains of 0.0044 and 0.0073 versus IGlar U300 in
T1DM and T2DMBOT, respectively.
In T2DMB/B, the incremental cost per incre-
mental QALY gained with IDeg versus IGlar
U300 is estimated at £17,918 (£154.50 higher
annual per patient cost and 0.0084 QALY gain
with IDeg versus IGlar U300). This result falls
below the commonly accepted threshold for
cost-effectiveness. Even when no hypogly-
caemia benefit for IDeg is assumed, it is less
costly than IGlar U300 in T1DM and T2DMBOT,
with an annual treatment cost difference of
-£53.15 and -£14.21, respectively. In T2DMB/
B, if no hypoglycaemia benefit is assumed, the
annual treatment cost difference for IDeg versus
IGlar U300 is £159.51.
PROBABILISTIC SENSITIVITY
ANALYSIS
In T1DM, the PSA results indicate that IDeg is
dominant over IGlar U100. All the results are
cost-saving, with some results showing health
gains and some a negative QALY gain (Fig. 2a).
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The cost-effectiveness acceptability curve
(CEAC) shows that the chances of IDeg being
cost-effective are approximately 65–70% at any
willingness to pay threshold in excess of
£10,000.
In T2DMBOT, the results indicate that IDeg is
dominant over IGlar U100, with the vast
majority of simulations resulting in a positive
QALY gain and a decrease in costs (Fig. 2b). The
CEAC shows that in excess of 99% of the results
are cost-effective at a willingness to pay
threshold of just £10,000.
In T2DMB/B, the results indicate that IDeg
increases the annual per-patient cost in this
group of patients whilst also providing a benefit
in QALYs in the majority of simulations
Fig. 2 PSA results: cost-effectiveness scatterplots and acceptability curves
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(Fig. 2c). The CEAC shows that IDeg is cost-ef-
fective, with a probability of 62.5% and 76.8%
at a willingness to pay threshold of £20,000 and
£30,000, respectively.
DISCUSSION
This simple, short-term cost-utility analysis
suggests that the use of IDeg is highly likely to
be cost-effective compared with IGlar U100 in
the UK. IDeg is dominant (i.e. both more
effective and less costly) versus IGlar U100 in
patients with T1DM and patients with
T2DMBOT, and is cost-effective versus IGlar
U100 in patients with T2DMB/B (ICER £15,983/
QALY). In T1DM, lower costs are primarily dri-
ven by lower insulin costs, as a result of a lower
daily dose of IDeg. In T2DMBOT, lower overall
costs with IDeg are driven by lower costs of
severe hypoglycaemic events, due to the sig-
nificant reduction in the number of severe
hypoglycaemic events with IDeg versus IGlar
U100 in this patient group. Improvements in
clinical outcomes in all three patient groups are
a result of the reduced incidence of hypogly-
caemic events.
Sensitivity analyses demonstrate that the
results are robust and invariant to changes in
most of the input parameters. In patients with
T1DM and T2DMBOT, the ICER remains domi-
nant in the majority of analyses conducted. In
patients with T2DMB/B, the ICER remains below
the threshold of £20,000–£30,000/QALY gained
in almost all analyses. PSA shows that there is a
high probability that IDeg will be cost-effective
versus IGlar U100 in all three patient groups.
With a number of new insulin formulations
on the market, decision-making based on clin-
ical and economic evidence is essential, as
healthcare providers aim to maximise health
outcomes with restricted budgets. Scenario
analyses were conducted to estimate cost-effec-
tiveness versus two new-to-market basal insulin
analogues. In the absence of a direct compar-
ison between IDeg and these new comparators,
the analyses were based on available data and
plausible assumptions, and the results should be
interpreted accordingly. In patients with T1DM
and T2DMBOT, IDeg is likely to be highly
cost-effective versus IGlar biosimilar (Aba-
saglar) and dominant to IGlar U300 (Toujeo),
and in T2DMB/B, IDeg is cost-effective versus
both comparators with ICERs below the
£20,000/QALY gained threshold. IDeg has
recently been approved by the Scottish Medici-
nes Consortium and All Wales Medicines Strat-
egy Group for the treatment of diabetes mellitus
in adults in Scotland [41] and Wales [42],
respectively.
Cost-effectiveness analyses of diabetes inter-
ventions are traditionally performed by esti-
mating the long-term clinical consequences as a
function of differences in glycaemic control.
However, the treat-to-target clinical trial design
enforces a similar level of glycaemic control
across interventions, resulting in non-inferior
and non-significant differences, and thus ren-
dering long-term modelling based on HbA1c
differences inappropriate. This short-term
approach focuses on the impact of other
important aspects of insulin therapy such as
hypoglycaemia and dosing, and enables eco-
nomic evaluation of new insulin analogues
based on data derived from treat-to-target
studies. Although a short-term (1 year) time
horizon is used, results are not only applicable
for the cost-effectiveness of IDeg within the first
year of treatment. As the model can be repli-
cated for subsequent years, the outcomes rep-
resent the average annual cost-effectiveness.
This model has been previously used to
evaluate the cost-effectiveness of IDeg versus
IGlar U100 in patients with T1DM and T2DM.
In this re-evaluation, a number of revisions were
made to the modelling framework. As a conse-
quence of the ultra-long duration of action, flat
and stable action profile [10, 11], and lower
variability over the day than IGlar U100 [12],
there is evidence to suggest that titration and
maintenance with IDeg is possible with fewer
weekly SMBG tests [43]. Cost savings may
therefore be made through the use of fewer
SMBG tests with IDeg; however, a change in
testing behaviour may take time to translate
into clinical practice, so it was excluded from
this re-evaluation. Similarly, if administration
at the same time of day is not possible, the
ultra-long and stable action profile of IDeg
allows for flexibility of dosing time without
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compromising efficacy or risk of hypogly-
caemia. In the previous evaluation, an estimate
of the utility benefit associated with the option
of flexible dosing with IDeg was applied for the
calculation of QALYs. This was excluded from
the current re-evaluation in recognition that
not all patients will benefit from this attribute,
but it was included as a sensitivity analysis. The
potential for flexible dosing may translate into
additional economic value in patients who find
it difficult to adhere to a strict dosing regimen
(e.g. shift workers or frequent travellers), or
those who rely on a carer to administer their
insulin.
As with all modelling studies, the limitations
of this study should be considered when putting
the findings into context. Meta-analyses of
clinical trial data are used in our model to
increase the sample size and power of the
parameter estimates derived from individual
studies. However, it is assumed that the data
collected in the clinical trials is replicated in
routine clinical practice. The clinical trials used
a treat-to-target approach, where insulin doses
were titrated until the glycaemic target was
achieved. In clinical practice, optimal glycaemic
control may not be achieved for a variety of
reasons, such as non-adherence or missed clinic
appointments. However, the extensive sensi-
tivity analyses suggest that the conclusions are
robust and invariant to changes in a variety of
alternative modelling assumptions.
Real-world studies are a valuable source of
evidence and are increasingly being used to
complement clinical trial data in the deci-
sion-making process. A study has evaluated the
real-world cost-effectiveness of switching
patients with T1DM (n = 35) to IDeg in clinical
practice in the UK [15]. The long-term
cost-effectiveness of IDeg versus IGlar U100 or
insulin detemir in people with T1DM experi-
encing hypoglycaemia was evaluated using the
IMS CORE Diabetes Model [44]. The model was
run over a patient lifetime and the benefits and
costs were discounted at 3.5%. Over a lifetime,
treatment with IDeg is less costly and more
effective than treatment with IGlar/insulin
detemir (dominant). This is driven by a
reduction in HbA1c and the lower rate of
hypoglycaemia [15]. This evaluation of
real-world data supports that from the clinical
trial programme, and indicates that IDeg is a
cost-effective alternative to IGlar in patients
experiencing problems with hypoglycaemia in
clinical practice. The analysis was conducted
using the old pack price of IDeg (£72.00/pack);
thus, with the recent price reduction to
£46.60/pack, IDeg represents even better value.
Another study evaluated the cost-effectiveness
of switching to IDeg from other basal insulins
in people with T1DM (n = 476) using real--
world evidence from Sweden [45]. The Core
Diabetes Model was used to predict long-term
outcomes, and the costs associated with treat-
ment and long-term complications of diabetes
were included. Again, the results of the analy-
sis showed that IDeg was less costly than the
patients’ previous insulin treatment and was
associated with improvements in health-re-
lated quality of life (dominant). Thus, for
patients with T1DM in Sweden, switching to
IDeg was cost-effective when compared with
treatment with their prior insulin.
Another economic assessment which may be
informative for decision makers is a budget
impact analysis. A budget impact analysis esti-
mates the financial consequences of adopting a
new intervention for local, regional and
national budgets. It identifies the size of the
population affected by the intervention and the
effect of implementation on costs over the short
term. This study calculated the total cost per
patient per year, comprisiing the annual phar-
macy cost and the annual cost of hypogly-
caemic events, for a patient with T1DM,
T2DMBOT or T2DMB/B treated with IDeg or IGlar
U100 (Table 4). These costs can be utilised to
calculate the annual budget impact of treat-
ment with IDeg or IGlar U100 for a defined local
patient population, whereby the annual per
patient cost is simply multiplied by the number
of patients treated. The breakdown of costs in
Table 4 allows the impact on different budgets
to be calculated.
In phase 3a clinical trials, IDeg showed
equivalent reductions in HbA1c with a lower risk
of hypoglycaemia versus IGlar U100 [13, 14].
The hypoglycaemia benefits of IDeg have also
been reported in real-world clinical practice,
with reductions of up to 90% observed in
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patients switching to IDeg because of problems
with hypoglycaemia on IGlar or insulin detemir
[15]. Two phase 3b studies, SWITCH 1 and
SWITCH 2, in patients with T1DM and T2DM,
respectively, were designed to confirm the
hypoglycaemia benefit observed with IDeg ver-
sus IGlar U100 in the phase 3a studies [46, 47].
These studies sought to investigate the efficacy
and safety of IDeg in diabetes populations with
an increased risk of hypoglycaemia and to assess
the safety of IDeg in transfers from other basal
insulins. IDeg demonstrated non-inferiority to
IGlar U100 in glycaemic control (HbA1c) in
patients with T1DM and T2DM in these
treat-to-target trials. Equivalent reductions in
HbA1c were achieved with a lower total daily
insulin dose at end-of-trial, and with a lower
risk of hypoglycaemic episodes versus IGlar
U100 [46, 47]. An economic evaluation of the
data from these clinical trials would be benefi-
cial to demonstrate the cost-effectiveness of
IDeg in these high hypoglycaemia risk
populations.
CONCLUSIONS
Based on this short-term economic model, IDeg
is a cost-effective alternative to IGlar U100 for
patients with T1DM and T2DM in the UK.
Results also suggest that IDeg is likely to be
cost-effective versus two new-to-market basal
insulin analogues. IDeg may particularly benefit
those suffering with hypoglycaemia while on
other basal insulin analogues, or may prove
useful to patients who would benefit from the
additional flexibility.
ACKNOWLEDGEMENTS
The study and article processing charges were
funded by Novo Nordisk. The authors
acknowledge writing and editorial support from
Carrie Fidler of DRG Abacus (sponsored by
Novo Nordisk).
All authors had full access to all of the data in
this study and take complete responsibility for
the integrity of the data and accuracy of the
data analysis.
All named authors meet the International
Committee of Medical Journal Editors (ICMJE)
criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval for the
version to be published.
Disclosures. All authors contributed to
study design, data collection and analysis, and
interpretation of results, as well as to the writing
and final approval of this manuscript.
Marc Evans has received honoraria and re-
search awards from Novo Nordisk, Sanofi Aven-
tis, MSD and Novartis. Barrie Chubb is an
employee and shareholder of Novo Nordisk.
Jens Gundgaard is an employee and shareholder
of Novo Nordisk.
Compliance with Ethics Guidelines. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Data Availability. All data generated or
analysed during this study are included in this
published article/as supplementary information
files.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Zhang P, Zhang X, Brown J, et al. Global healthcare
expenditure on diabetes for 2010 and 2030. Dia-
betes Res Clin Pract. 2010;87:293–301.
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D.
Estimating the current and future costs of type 1
and type 2 diabetes in the UK, including direct
288 Diabetes Ther (2017) 8:275–291
health costs and indirect societal and productivity
costs. Diabet Med. 2012;29:855–62.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil
HA. 10-year follow-up of intensive glucose control
in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
4. Nathan DM, Cleary PA, Backlund JY, et al. Intensive
diabetes treatment and cardiovascular disease in
patients with type 1 diabetes. N Engl J Med.
2005;353:2643–53.
5. National Institute for Health and Care Excellence
(NICE).NICEGuideline 17. Type 1diabetes in adults:
diagnosis andmanagement. 2015. http://www.nice.
org.uk/guidance/ng17. Accessed 23 Dec 2016.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Man-
agement of hyperglycemia in type 2 diabetes, 2015:
a patient-centered approach: update to a position
statement of the American Diabetes Association
and the European Association for the Study of
Diabetes. Diabetes Care. 2015;38:140–9.
7. NHS Health, Social Care Information Centre.
Quality and outcomes framework for diabetes
2013–14. https://mqi.ic.nhs.uk/IndicatorDefault
View.aspx?ref=1.09.04.21. Accessed 23 Dec 2016.
8. Davies M, Gagliardino J, Gray L, Khunti K, Mohan
V, Hughes R. Real-world factors affecting adherence
to insulin therapy in patients with type 1 or type 2
diabetes mellitus: a systematic review. Diabet Med.
2013;30:512–24.
9. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to
insulin therapy among patients and providers:
results of the cross-national Diabetes Attitudes,
Wishes, and Needs (DAWN) study. Diabetes Care.
2005;28:2673–9.
10. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H.
Ultra-long-acting insulin degludec has a flat and
stable glucose-lowering effect in type 2 diabetes.
Diabetes Obes Metab. 2012;14:944–50.
11. Haahr H, Heise T. A review of the pharmacological
properties of insulin degludec and their clinical
relevance. Clin Pharmacokinet. 2014;53:787–800.
12. Heise T, Hermanski L, Nosek L, Feldman A,
Rasmussen S, Haahr H. Insulin degludec: four
times lower pharmacodynamic variability than
insulin glargine under steady-state conditions in
type 1 diabetes. Diabetes Obes Metab. 2012;14:
859–64.
13. Ratner R, Gough SC, Mathieu C, et al. Hypogly-
caemia risk with insulin degludec compared with
insulin glargine in type 2 and type 1 diabetes: a
pre-planned meta-analysis of phase 3 trials. Dia-
betes Obes Metab. 2013;15:175–84.
14. Vora J, Christensen T, Rana A, Bain SC. Insulin
degludec versus insulin glargine in type 1 and type
2 diabetes mellitus: a meta-analysis of endpoints in
phase 3a trials. Diabetes Ther. 2014;5:435–46.
15. Evans M, McEwan P, Foos V. Insulin degludec early
clinical experience: does the promise from the
clinical trials translate into clinical practice-a
case-based evaluation. J Med Econ. 2015;18:96–105.
16. Sassi F. Calculating QALYs, comparing QALY and
DALY calculations. Health Policy Plan.
2006;21:402–8.
17. National Institute for Health and Clinical Excel-
lence. Measuring effectiveness and cost-effective-
ness: the QALY. 2010. http://www.nice.org.uk/
newsroom/features/measuringeffectivenessandcost
effectivenesstheqaly.jsp. Accessed 23 Dec 2016.
18. Ericsson A, Pollock RF, Hunt B, Valentine WJ.
Evaluation of the cost-utility of insulin degludec vs
insulin glargine in Sweden. J Med Econ.
2013;16:1442–52.
19. Evans M, Wolden M, Gundgaard J, Chubb B,
Christensen T. Cost-effectiveness of insulin deglu-
dec compared with insulin glargine for patients
with type 2 diabetes treated with basal insulin—
from the UK health care cost perspective. Diabetes
Obes Metab. 2014;16:366–75.
20. Evans M, Wolden M, Gundgaard J, Chubb B,
Christensen T. Cost-effectiveness of insulin deglu-
dec compared with insulin glargine in a basal-bolus
regimen in patients with type 1 diabetes mellitus in
the UK. J Med Econ. 2015;18:56–68.
21. The Forum for Injection Technique (FIT). Diabetes
care in the UK: the first UK injection technique




22. Allbright E, Desmond R, Bell D. Efficacy of conver-
sion from bedtime NPH insulin injection to once-
or twice-daily injections of insulin glargine in type
1 diabetic patients using basal/bolus therapy. Dia-
betes Care. 2004;27:632–3.
23. Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved
glycemic control without an increase in severe
hypoglycemic episodes in intensively treated
patients with type 1 diabetes receiving morning,
evening, or split dose insulin glargine. Diabetes Res
Clin Pract. 2004;66:49–56.
24. Dhatariya KK, Yeong J. Improved glycaemic control
for patients on a twice daily dosing regimen of
insulin glargine compared to those on a once daily
dosing regimen. Poster presentation at European
Diabetes Ther (2017) 8:275–291 289
Association for the Study of Diabetes, Stockholm
2010. Diabetologia. 2010;53:S390.
25. UK Hypoglycaemia Study Group. Risk of hypogly-
caemia in types 1 and 2 diabetes: effects of treat-
ment modalities and their duration. Diabetologia.
2007;50:1140–7.
26. Evans M, Khunti K, Mamdani M, et al. Health-re-
lated quality of life associated with daytime and
nocturnal hypoglycaemic events: a time trade-off
survey in five countries. Health Qual Life Out-
comes. 2013;11:90.
27. Haymarket Media Group. Monthly Index of Medi-
cal Specialities (MIMS). 2016. http://www.mims.co.
uk/. Accessed 23 Dec 2016.
28. Hammer M, Lammert M, Mejias SM, Kern W, Frier
BM. Costs of managing severe hypoglycaemia in
three European countries. J Med Econ.
2009;12:281–90.
29. Chubb B, Tikkanen C. The cost of non-severe
hypoglycaemia In Europe. Value Health.
2015;18:A611.
30. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lam-
mert M, McEwan P. Multivariate models of
health-related utility and the fear of hypoglycaemia
in people with diabetes. Curr Med Res Opin.
2006;22:1523–34.
31. Evans M, Jensen HH, Bogelund M, Gundgaard J,
Chubb B, Khunti K. Flexible insulin dosing
improves health-related quality-of-life (HRQoL): a
time trade-off survey. J Med Econ.
2013;16:1357–65.
32. Boye KS, Matza LS, Walter KN, Van Brunt K, Pals-
grove AC, Tynan A. Utilities and disutilities for
attributes of injectable treatments for type 2 dia-
betes. Eur J Health Econ. 2011;12:219–30.
33. European Commission. What you need to know
about biosimilar medicinal products. A consensus







ities%E2%80%99?perspective. Accessed 23 Dec
2016.




Accessed 23 Dec 2016.




Accessed 23 Dec 2016.
36. Home PD, Bergenstal RM, Bolli GB, et al. New
insulin glargine 300 units/mL versus glargine 100
units/mL in people with type 1 diabetes: a ran-
domized, phase 3a, open-label clinical trial (edition
4). Diabetes Care. 2015;38:2217–25.
37. Bolli GB, Riddle MC, Bergenstal RM, et al. New
insulin glargine 300 U/ml compared with glargine
100 U/ml in insulin-naive people with type 2 dia-
betes on oral glucose-lowering drugs: a randomized
controlled trial (edition 3). Diabetes Obes Metab.
2015;17:386–94.
38. Riddle MC, Bolli GB, Ziemen M, et al. New insulin
glargine 300 units/mL versus glargine 100 units/mL
in people with type 2 diabetes using basal and
mealtime insulin: glucose control and hypo-
glycemia in a 6-month randomized controlled trial
(edition 1). Diabetes Care. 2014;37:2755–62.
39. Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety
and efficacy of insulin detemir in clinical practice:
14-week follow-up data from type 1 and type 2
diabetes patients in the PREDICTIVE European
cohort. Int J Clin Pract. 2007;61:523–8.
40. Frier BM, Jensen MM, Chubb BD. Hypoglycaemia in
adults with insulin-treated diabetes in the UK:
self-reported frequency and effects. Diabet Med.
2016;33(8):1125–32.
41. Scottish Medicines Consortium. SMC advice no.
856/13. Insulin degludec (Tresiba) 100units/mL
solution for injection in pre-filled pen or cartridge




pdf. Accessed 23 Dec 2016.
42. AWMSG. Final appraisal recommendation advice
no: 2816. Insulin degludec (Tresiba) 100 units/ml
and 200 units/ml solution for injection in prefilled
pen (FlexTouch) or 100 units/ml solution for
injection in cartridge (Penfill). http://www.
awmsg.org/awmsgonline/app/appraisalinfo/3158.
Accessed 23 Dec 2016.
43. Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo
Francisco AM, Rothman J. Insulin degludec once--
daily in type 2 diabetes: simple or step-wise titration
(begin: once simple use). Adv Ther. 2013;30:607–22.
44. Palmer AJ, Roze S, Valentine WJ, et al. The CORE
Diabetes Model: projecting long-term clinical out-
comes, costs and cost-effectiveness of interventions
290 Diabetes Ther (2017) 8:275–291
in diabetes mellitus (types 1 and 2) to support
clinical and reimbursement decision-making. Curr
Med Res Opin. 2004;20(Suppl 1):S5–26.
45. Gundgaard J, Landstedt-Hallin L, Ericsson A˚, Ell-
fors-Zetterlund S. Cost-effectiveness of switching to
Tresiba from other basal insulins: evidence from
Swedish real-world data. Oral presentation #11. In
EASD 52nd Annual Meeting, Munich, Germany;
September 12–16, 2016, p. 12–16.
46. Lane W, Bailey TS, Gerety G, et al. SWITCH 1:
reduced hypoglycemia with insulin degludec (IDeg)
versus insulin glargine (IGlar), both U100, in
patients with T1D at high risk of hypoglycemia: a
randomized, double-blind, cross-over trial. 87-LB.
Presented at the ADA 76th Annual Scientific Ses-
sions, New Orleans, LA, USA; June 10–14, 2016,
p. 10–14.
47. Wysham C, Bhargava A, Chaykin L, et al. SWITCH
2: reduced hypoglycemia with insulin degludec
(IDeg) versus insulin glargine (IGlar), both U100, in
patients with T2D at high risk of hypoglycemia: a
randomized, double-blind, crossover trial. 90-LB.
Presented at the ADA 76th Annual Scientific Ses-
sions, New Orleans, LA, USA; June 10–14, 2016,
p. 10–14.
Diabetes Ther (2017) 8:275–291 291
